Please assess the completion status of the following clinical trial:

Trial Title: Phase II, Dose Finding Study of GTx-758

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be between age 45 and 80 years of age~2. Be able to communicate effectively with the study personnel~3. ECOG is ≤2~4. Screening serum total testosterone ≥150 ng/dL~5. Have prostate cancer, confirmed by pathology report~6. Have not been treated with ADT (chemical or surgical). If a subject has been treated with LHRHa for ≤6 months duration and that treatment was ≥1 years prior to the screening, the subject may be considered for the study.~7. Have a clinical indication for the initiation ADT.~8. Give written informed consent prior to any study specific procedures~9. Subjects must agree to use acceptable methods of contraception:~   * If their female partners are pregnant or lactating acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azospermia) a condom with spermicidal foam/gel/film/cream/suppository should be used.~  * If the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository \[i.e. double barrier method of contraception\], surgical sterilization (vasectomy with documentation of azospermia) and a double barrier method (condom used with spermicidal foam/gel/film/cream/suppository), the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a double barrier method (condom used with spermicidal foam/gel/film/cream/suppository).~  * If the female partner has undergone documented tubal ligation (female sterilization), a double barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used.~  * If the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a double barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used.~Exclusion Criteria:~1. Known hypersensitivity or allergy to estrogen or estrogen like drugs~2. Have, in the judgment of the Investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol~3. History of abnormal blood clotting, Factor V Leiden clotting disorder, thrombotic disease (venous or arterial thrombotic events such as history of myocardial infarct (MI), stroke, deep vein thrombosis (DVT), and/or pulmonary embolus (PE)) NOTE: if there is evidence of an MI on the ECG that is not documented in the medical history or there is a history of MI greater than three years ago that has completely resolved, the eligibility of this subject per this exclusion criterion is an investigator decision and may require a consultation with a cardiologist.~4. Have ALT or AST above 2 times the upper limit of normal (ULN)~5. Have alkaline phosphatase greater than 3 times ULN and/or total bilirubin levels above 2 mg/dL at baseline~6. Patients cannot have brain or spinal cord metastases~7. Patients cannot have or be at high risk for spinal cord compression from bone metastases.~8. Received an investigational drug within a period of 90 days prior to enrollment in the study~9. Received the study medication previously~10. Currently taking testosterone, testosterone-like agents or antiandrogens, including 5-alpha reductase inhibitors (the subject may be considered for randomization after a 4 week washout period prior to randomization)~11. Currently taking Saw Palmetto or PC-SPES (the subject may be considered for randomization after a 4 week washout period prior to randomization)~12. Have taken diethylstilbestrol or other estrogen products within the previous 12 months prior to randomization into this study~13. Have taken body building or fertility supplements within 4 weeks of admission into the study (steroids and steroid like supplements)~14. Have a history of cancer other than prostate cancer, superficial bladder cancer (with no recurrence in the last 5 years) and/or non-melanoma carcinoma of the skin.~15. QTcB \>480 msec, If the first QTcB reading exceeds 480 msec two additional ECGs are to be performed separated at least 5 min apart, then take the average of the three QTcB readings to determine if the subject satisfies the above criteria. If the average QTcB reading is \> 480 msec then the subject is excluded.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1000mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg (Type: EXPERIMENTAL): 1000mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg
- 1000mg Loading DoseGTx-758 BID and Maintenance Dose 2000mg (Type: EXPERIMENTAL): 1000mg Loading Dose GTx-758 BID and Maintenance Dose 2000mg
- 1500 mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg (Type: EXPERIMENTAL): 1500 mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg
- 1500 mg Loading Dose GTx-758 BID and Maintenance Dose 2000mg (Type: EXPERIMENTAL): 1500 mg Loading Dose GTx-758 BID and Maintenance Dose 2000mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval